Dipna Pharmachem (543594)

Score breakdown: P/E: 3/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

At ₹7.70, with a market cap of only ₹19 Cr, the market has already marked Dipna Pharmachem down harshly; the stock trades near the bottom of its ₹7.10–₹25.00 52-week range. The trailing P/E of 11.60 looks cheap, and a 314.71% profit growth figure catches the eye. But Buffett's first rule is not to lose money, and Graham's rule is to have a margin of safety. Here I see a small pharma business with a real turnover—₹74 Cr in the latest quarter—but a net profit of just ₹1 Cr. That is roughly a 1.35% net margin. Such a thin margin leaves very little room for error. Sales are shrinking, down 18.85%, which is the opposite of what I want in a growing enterprise. The 6.64% ROCE is also modest; it tells me the company is not yet earning a high return on capital employed. The Piotroski F-score of 6/9 is acceptable, but it is the only comfort. With no dividend and no disclosed book value, debt/equity or promoter holding, I cannot apply my usual value tests. The PEG ratio of 0.04 is a red flag in disguise: Mr. Market is not paying for growth because it does not trust the earnings spike. This looks more like a possible turnaround than a wonderful business. I would insist on several quarters of positive, consistent earnings and stabilised sales before acting. The price may look like a cigar butt, but with a 70% drop from the high, the risk of a value trap is real. I need evidence that this profit is sustainable and capital is being deployed productively before I call it an investment.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer